Literature DB >> 1849087

An improved noninfectious murine skin model of organized granulomatous inflammation.

T Iida1, Y Nozaki, K Fukuyama, W L Epstein.   

Abstract

An improved model of granulomatous inflammation in skin was developed by second passage skin grafting of isolated, lyophilized skin granulomas, originally elicited in naive mice by inoculations of lyophilized hepatic schistosome egg granulomas. The tissue reaction is caused by a single exposure to a noninfectious, acellular granulomagenic stimulus and occurs in healthy mice free of systemic disease. The model should prove useful for isolation of granuloma initiation factor(s). Furthermore, because there is a time lag before new granuloma formation begins, a window exists for analytical dissection of the initiation process. In this study we described the responses of host cells by autoradiography, and light and electron microscopy. The activity of angiotensin-converting enzyme and proline-specific endopeptidase showed a modulation during granuloma formation. In addition we found that severe immunosuppression with high dose cyclosporine therapy did not alter granuloma formation, supporting the idea that initiation of organized granulomas is T-cell independent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849087     DOI: 10.1007/bf01958158

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  26 in total

1.  Immunosuppression and in vivo T cell function in granulomatous inflammation.

Authors:  A Fujioka; C Pincelli; A Hashimoto; K Fukuyama; W L Epstein
Journal:  Int Arch Allergy Appl Immunol       Date:  1989

2.  Granulomatous pulmonary lesions in patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii infection.

Authors:  W Blumenfeld; N Basgoz; W F Owen; D M Schmidt
Journal:  Ann Intern Med       Date:  1988-09-15       Impact factor: 25.391

3.  Low molecular weight eosinophil chemotactic factor in granulomatous liver of murine schistosomiasis.

Authors:  S Tsuda; K Fukuyama; W L Epstein
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

4.  Angiotensin-converting enzyme and other enzymes in livers of mice with experimental schistosomiasis.

Authors:  A Hara; K Fukuyama; W L Epstein
Journal:  Exp Mol Pathol       Date:  1981-10       Impact factor: 3.362

Review 5.  Immunopathology of Schistosoma mansoni infection.

Authors:  D L Boros
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

6.  T-cell independent transfer of organized granuloma formation.

Authors:  W L Epstein; M Okamoto; H Suya; K Fukuyama
Journal:  Immunol Lett       Date:  1986-11-17       Impact factor: 3.685

7.  Autotransplantation of hepatic granulomas into the skin of mice with Schistosoma mansoni infection.

Authors:  M Nishimura; W L Epstein; K Fukuyama
Journal:  J Invest Dermatol       Date:  1982-09       Impact factor: 8.551

8.  Pulmonary sarcoidosis associated with acquired humoral and cellular immunodeficiency.

Authors:  G R Burmester; M Gramatzki; J von Gernler; O Bartels; J R Kalden
Journal:  Clin Immunol Immunopathol       Date:  1985-12

9.  Eggs of Schistosoma mansoni stimulate endothelial cell proliferation in vitro.

Authors:  D O Freedman; E A Ottesen
Journal:  J Infect Dis       Date:  1988-09       Impact factor: 5.226

10.  Post-proline cleaving enzyme. Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man.

Authors:  T Yoshimoto; K Ogita; R Walter; M Koida; D Tsuru
Journal:  Biochim Biophys Acta       Date:  1979-08-15
View more
  2 in total

1.  Characterization of two dipeptidases purified from hepatic schistosome egg granulomas in mice. Leukotriene D4 hydrolases of granulomatous tissue.

Authors:  N Sato; Y Ito; T Iida; K Fukuyama; W L Epstein
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

2.  Isolation and characterization of granuloma initiation factor.

Authors:  M A Fung; N Sato; T Tida; K Fukuyama; W L Epstein
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.